[
  {
    "sentence": "The condition is characterized by abnormal clonal expansion and aberrant differentiation of immature clonal myeloid cells (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Artificial Intelligence (AI) in Cancer Therapy\nAI is poised to disrupt how big data is analysed and will benefit cancer management, including new drug discovery, drug repurposing and optimum dose administration (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "HTS-based DST using PDCs followed by QPOP and CURATE.AI to identify optimal drug combinations and dosing, together with incorporating genomic and transcriptomic profiling to the DST to create a functional taxonomy based on comprehensive drug response and mutation profile will be an important next step toward devising new treatment strategies in blood cancer (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The condition is characterized by abnormal clonal expansion and aberrant differentiation of immature clonal myeloid cells (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Artificial Intelligence (AI) in Cancer Therapy\nAI is poised to disrupt how big data is analysed and will benefit cancer management, including new drug discovery, drug repurposing and optimum dose administration (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "HTS-based DST using PDCs followed by QPOP and CURATE.AI to identify optimal drug combinations and dosing, together with incorporating genomic and transcriptomic profiling to the DST to create a functional taxonomy based on comprehensive drug response and mutation profile will be an important next step toward devising new treatment strategies in blood cancer (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The condition is characterized by abnormal clonal expansion and aberrant differentiation of immature clonal myeloid cells (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Artificial Intelligence (AI) in Cancer Therapy\nAI is poised to disrupt how big data is analysed and will benefit cancer management, including new drug discovery, drug repurposing and optimum dose administration (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "HTS-based DST using PDCs followed by QPOP and CURATE.AI to identify optimal drug combinations and dosing, together with incorporating genomic and transcriptomic profiling to the DST to create a functional taxonomy based on comprehensive drug response and mutation profile will be an important next step toward devising new treatment strategies in blood cancer (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The condition is characterized by abnormal clonal expansion and aberrant differentiation of immature clonal myeloid cells (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Artificial Intelligence (AI) in Cancer Therapy\nAI is poised to disrupt how big data is analysed and will benefit cancer management, including new drug discovery, drug repurposing and optimum dose administration (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "HTS-based DST using PDCs followed by QPOP and CURATE.AI to identify optimal drug combinations and dosing, together with incorporating genomic and transcriptomic profiling to the DST to create a functional taxonomy based on comprehensive drug response and mutation profile will be an important next step toward devising new treatment strategies in blood cancer (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The condition is characterized by abnormal clonal expansion and aberrant differentiation of immature clonal myeloid cells (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Artificial Intelligence (AI) in Cancer Therapy\nAI is poised to disrupt how big data is analysed and will benefit cancer management, including new drug discovery, drug repurposing and optimum dose administration (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "HTS-based DST using PDCs followed by QPOP and CURATE.AI to identify optimal drug combinations and dosing, together with incorporating genomic and transcriptomic profiling to the DST to create a functional taxonomy based on comprehensive drug response and mutation profile will be an important next step toward devising new treatment strategies in blood cancer (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The condition is characterized by abnormal clonal expansion and aberrant differentiation of immature clonal myeloid cells (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Artificial Intelligence (AI) in Cancer Therapy\nAI is poised to disrupt how big data is analysed and will benefit cancer management, including new drug discovery, drug repurposing and optimum dose administration (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "HTS-based DST using PDCs followed by QPOP and CURATE.AI to identify optimal drug combinations and dosing, together with incorporating genomic and transcriptomic profiling to the DST to create a functional taxonomy based on comprehensive drug response and mutation profile will be an important next step toward devising new treatment strategies in blood cancer (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The condition is characterized by abnormal clonal expansion and aberrant differentiation of immature clonal myeloid cells (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Artificial Intelligence (AI) in Cancer Therapy\nAI is poised to disrupt how big data is analysed and will benefit cancer management, including new drug discovery, drug repurposing and optimum dose administration (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "HTS-based DST using PDCs followed by QPOP and CURATE.AI to identify optimal drug combinations and dosing, together with incorporating genomic and transcriptomic profiling to the DST to create a functional taxonomy based on comprehensive drug response and mutation profile will be an important next step toward devising new treatment strategies in blood cancer (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The condition is characterized by abnormal clonal expansion and aberrant differentiation of immature clonal myeloid cells (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Artificial Intelligence (AI) in Cancer Therapy\nAI is poised to disrupt how big data is analysed and will benefit cancer management, including new drug discovery, drug repurposing and optimum dose administration (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "HTS-based DST using PDCs followed by QPOP and CURATE.AI to identify optimal drug combinations and dosing, together with incorporating genomic and transcriptomic profiling to the DST to create a functional taxonomy based on comprehensive drug response and mutation profile will be an important next step toward devising new treatment strategies in blood cancer (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The condition is characterized by abnormal clonal expansion and aberrant differentiation of immature clonal myeloid cells (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "The condition is characterized by abnormal clonal expansion and aberrant differentiation of immature clonal myeloid cells (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Artificial Intelligence (AI) in Cancer Therapy\nAI is poised to disrupt how big data is analysed and will benefit cancer management, including new drug discovery, drug repurposing and optimum dose administration (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "AI is poised to disrupt how big data is analysed and will benefit cancer management, including new drug discovery, drug repurposing and optimum dose administration (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "HTS-based DST using PDCs followed by QPOP and CURATE.AI to identify optimal drug combinations and dosing, together with incorporating genomic and transcriptomic profiling to the DST to create a functional taxonomy based on comprehensive drug response and mutation profile will be an important next step toward devising new treatment strategies in blood cancer (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "HTS-based DST using PDCs followed by QPOP and CURATE.AI to identify optimal drug combinations and dosing, together with incorporating genomic and transcriptomic profiling to the DST to create a functional taxonomy based on comprehensive drug response and mutation profile will be an important next step toward devising new treatment strategies in blood cancer (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  }
]